Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical transfer of AGuIX®-based radiation treatments for locally advanced cervical cancer: MR quantification and in vitro insights in the NANOCOL clinical trial framework.
Maury P, Mondini M, Chargari C, Darricau A, Shahin M, Ammari S, Bockel S, Genestie C, Wu TD, Lux F, Tillement O, Lacombe S, Deutsch E, Robert C, Porcel E. Maury P, et al. Among authors: genestie c. Nanomedicine. 2023 Jun;50:102676. doi: 10.1016/j.nano.2023.102676. Epub 2023 Apr 20. Nanomedicine. 2023. PMID: 37084803
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
Blanc-Durand F, Yaniz-Galende E, Llop-Guevara A, Genestie C, Serra V, Herencia-Ropero A, Klein C, Berton D, Lortholary A, Dohollou N, Desauw C, Fabbro M, Malaurie E, Bonichon-Lamaichhane N, Dubot C, Kurtz JE, de Rauglaudre G, Raban N, Chevalier-Place A, Ferron G, Kaminsky MC, Kramer C, Rouleau E, Leary A. Blanc-Durand F, et al. Among authors: genestie c. Gynecol Oncol. 2023 Aug;175:194. doi: 10.1016/j.ygyno.2023.05.058. Epub 2023 Jun 2. Gynecol Oncol. 2023. PMID: 37271667 No abstract available.
Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma.
Christinat Y, Ho L, Clément S, Genestie C, Sehouli J, Cinieri S, Gonzalez Martin A, Denison U, Fujiwara K, Vergote I, Tognon G, Hietanen S, Ray-Coquard I, Pujade-Lauraine E, McKee TA. Christinat Y, et al. Among authors: genestie c. JCO Precis Oncol. 2023 Jun;7:e2200555. doi: 10.1200/PO.22.00555. JCO Precis Oncol. 2023. PMID: 37364234 Free PMC article.
A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers.
Niyoteka S, Seban RD, Rouhi R, Scarsbrook A, Genestie C, Classe M, Carré A, Sun R, La Greca Saint-Esteven A, Chargari C, McKenna J, McDermott G, Malinen E, Tanadini-Lang S, Guckenberger M, Guren MG, Lemanski C, Deutsch E, Robert C. Niyoteka S, et al. Among authors: genestie c. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4010-4023. doi: 10.1007/s00259-023-06320-2. Epub 2023 Aug 26. Eur J Nucl Med Mol Imaging. 2023. PMID: 37632562
Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.
Pautier P, Genestie C, Fizazi K, Morice P, Mottet C, Haie-Meder C, Le Cesne A, Lhommé C. Pautier P, et al. Among authors: genestie c. Int J Gynecol Cancer. 2002 Nov-Dec;12(6):749-54. doi: 10.1046/j.1525-1438.2002.01144.x. Int J Gynecol Cancer. 2002. PMID: 12445254
155 results